prone plaques. This close association with plaque activity and low correlation with circulating inflammatory markers suggests specificity of Lp-PLA 2 for vascular inflammation. 3 The association between elevated Lp-PLA 2 levels and both incident coronary heart disease and ischemic stroke is well established. 4 The association of Lp-PLA 2 with incident peripheral arterial disease (PAD) however has not been similarly assessed. Current evidence suggests a relationship between higher Lp-PLA 2 concentrations and increased risk of incident PAD exists but is limited to a single prospective study of elderly, predominantly white individuals. 5 In this study a significant p-value for interaction was noted, however, between Lp-PLA 2 mass and black race for the outcome of incident PAD in this study and the association of Lp-PLA 2 mass with incident PAD was not significant for this subgroup.
8 million people in the United States alone and over 200 million people worldwide are estimated to have PAD. 6, 7 Prevalence of PAD varies substantially according to age and ethnicity with significantly higher rates reported in older populations and African American individuals. [8] [9] [10] Established risk factors alone do not explain ethnic-specific variations in PAD prevalence. 10, 11 It is important to determine if high Lp-PLA 2 levels are associated with the development of PAD as well. If an association is observed, future studies could investigate if these individuals may benefit from more intensive measures to modify cardiovascular risk and, potentially, pharmacologic inhibition of Lp-PLA 2 .
The Atherosclerosis Risk in Communities (ARIC) offers an opportunity to prospectively examine the relationship between Lp-PLA 2 levels and the development of PAD in a large, well-defined population with long-term follow-up and better explore whether associations may differ by race. Ankle-brachial index The ABI was measured on nearly all participants at visit 1 (96%), on a select random number of participants at visits 3 (n=4197), 4 (n=5882), and most participants at visit 5 (86%). At visits 1 and 5, ABI was computed by dividing the average of ankle SBP measurements by the average of brachial SBP measurements. Two ankle BP measurements were taken 5 to 8 min apart at the posterior tibial artery in a randomly selected leg while the participant was prone. Two brachial artery BP were measured, usually in the right arm, with the participant supine. At visits 3 and 4, the ABI was defined as the ratio of a single ankle SBP to a single brachial BP, both measured with the participant supine. An abnormal ABI at baseline was defined as a recorded ABI of <0.9 or >1.4 at study visits 1, 3, or 4. Clinical PAD A positive Rose Questionnaire or a hospitalization ICD-9 code consistent with the diagnosis of PAD were used to determine clinical PAD. Rose Questionnaire Interviewers contacted participants annually by telephone to identify intermittent claudication symptoms and all hospitalizations. The Rose Questionnaire was used to evaluate whether participants had developed intermittent claudication, which was defined as exertional leg pain relieved within 10 min by resting. The comparison groups will be those who did not develop incident PAD and those who did develop incident PAD. Adjusting for age and sex, we will use a t-test for continuous variable and a χ 2 test for dichotomous variables to test differences between these two groups.
Main Hypothesis
2) Associations of Lp-PLA 2 activity with incident PAD Cox proportional hazards models will be used to investigate the association of baseline Lp-PLA 2 activity with incident PAD. In this analysis, we will model Lp-PLA 2 activity continuously (per SD increment) and also categorized into quartiles (lowest quartile as referent category). The analysis will be adjusted for age, sex, race, clinic site, smoking, alcohol consumption, diabetes, systolic and diastolic blood pressure, CHD, total and HDL cholesterol, BMI, physical activity, eGFR, anti-hypertensive medication, aspirin use, and statin use. The analyses will be additionally adjusted for CRP and fibrinogen.
3) Subgroup analyses
Step 2 will be repeated stratified by race (Whites and Blacks) for the incident PAD outcome. P-value for interaction will also be determined.
4) Sensitivity analysis
This will be performed to determine whether associations of Lp-PLA 2 activity differ based on how incident PAD is assessed (Clinical PAD and Low ABI analyzed separately) and to assess for possible bias introduced from the ABI not being measured in all participants at study visits. A) Clinical PAD:
Step 2 will be repeated for all eligible study participants as mentioned above to investigate the association of baseline Lp-PLA 2 activity with incident PAD defined only by the clinical PAD outcome B) Low ABI:
Step 2 will be repeated only in eligible individuals with ABI measured at both visit 4 and visit 5 to investigate the association of baseline Lp-PLA 2 activity with incident PAD defined only by the low ABI outcome. 5) Inflammatory markers AUC comparison will be calculated for predictive ability of Lp-PLA 2 activity beyond traditional RF's and markers of inflammation *ancillary studies are listed by number at http://www.cscc.unc.edu/aric/forms/ 12a. Manuscript preparation is expected to be completed in one to three years. If a manuscript is not submitted for ARIC review at the end of the 3-years from the date of the approval, the manuscript proposal will expire. 12b. The NIH instituted a Public Access Policy in April, 2008 which ensures that the public has access to the published results of NIH funded research. It is your responsibility to upload manuscripts to PubMed Central whenever the journal does not and be in compliance with this policy. Four files about the public access policy from http://publicaccess.nih.gov/ are posted in http://www.cscc.unc.edu/aric/index.php, under Publications, Policies & Forms. http://publicaccess.nih.gov/submit_process_journals.htm shows you which journals automatically upload articles to PubMed central.
